116
Registered trials
46
Recruiting
60
Completed trials
69
Sponsors
24
Countries
Phase III:
33
Phase II/III:
4
Phase II:
48
Phase I/II:
23
Phase IV:
3
Phase I (Other):
1
Phase I (FiH):
4
Oversight events:
6 serious breaches
6 temporary halts
5 urgent safety measures
1 unexpected event
3 corrective measures
across 11 trials
View oversight register →
Indications tested
Acute myeloid leukaemia
14
Myelodysplastic syndrome
7
Chronic lymphocytic leukaemia
5
B-cell small lymphocytic lymphoma
3
Mantle cell lymphoma
2
Chronic lymphocytic leukaemia recurrent
2
Chronic myelomonocytic leukaemia
2
Blastic plasmacytoid dendritic cell neoplasia
1
Chronic myeloid leukaemia
1
Non-Hodgkin's lymphoma
1
Renal cell carcinoma
1
Triple negative breast cancer
1
Sponsors using this IMP
AbbVie Deutschland GmbH & Co. KG
13
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
7
BeOne Medicines AG
5
Fondazione Gimema Franco Mandelli Onlus
4
University Of Cologne
4
AstraZeneca AB
3
F. Hoffmann-La Roche AG
3
Groupe Francophone Des Myelodysplasies
3
Janssen - Cilag International
3
Ospedale San Raffaele S.r.l.
3
Technische Universitat Dresden
3
Haemato Oncology Foundation For Adults Netherlands
2
All trials
116 total-
RVU120 Rollover Study Recruiting
Showing 1–24 of 116 trials